✦ LIBER ✦

6060 KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)

✍ Scribed by Salvatore, L.; Loupakis, F.; Fontanini, G.; Cremolini, C.; Stasi, I.; Fabbri, A.; Ciarlo, A.; Granetto, C.; Basolo, F.; Falcone, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6115 VEGF gene polymorphisms in the pred

✍ Loupakis, F.; Ruzzo, A.; Salvatore, L.; Canestrari, E.; Cremolini, C.; Santini, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

6081 Bevacizumab (BV) in combination wit

✍ Masi, G.; Salvatore, L.; Fornaro, L.; Vasile, E.; Baldi, G.G.; Stasi, I.; Ciarlo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

6096 POSTER FOLFOXIRI (Irinotecan, Oxali

✍ Fornaro, L.; Loupakis, F.; Lonardi, S.; Masi, G.; Salvatore, L.; Cremolini, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB

A randomized phase II trial assessing ir

✍ C. Pozzo; S. Pyrhönen; I. Bodrogi; J. Szanto; H. Kamica-Mlodkowska; H. Starkamma 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 119 KB

A triplet combination with irinotecan (C

✍ Saridaki, Z; Androulakis, N; Vardakis, N; Vamvakas, L; Kabouraki, E; Kalbakis, K 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 242 KB

6091 POSTER Final Results of a Multicent

✍ Samalin, E.; Bouche, O.; Thezenas, S.; Frangois, E.; Adenis, A.; Bennouna, J.; T 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB